[go: up one dir, main page]

WO2010093263A8 - Compositions and methods for the treatment and prevention of neoplastic disorders - Google Patents

Compositions and methods for the treatment and prevention of neoplastic disorders Download PDF

Info

Publication number
WO2010093263A8
WO2010093263A8 PCT/NZ2010/000014 NZ2010000014W WO2010093263A8 WO 2010093263 A8 WO2010093263 A8 WO 2010093263A8 NZ 2010000014 W NZ2010000014 W NZ 2010000014W WO 2010093263 A8 WO2010093263 A8 WO 2010093263A8
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
prevention
treatment
methods
neoplastic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NZ2010/000014
Other languages
French (fr)
Other versions
WO2010093263A1 (en
Inventor
Annette Lasham
Glen Reid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLIRNA BIOSCIENCES Ltd
Original Assignee
SOLIRNA BIOSCIENCES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLIRNA BIOSCIENCES Ltd filed Critical SOLIRNA BIOSCIENCES Ltd
Publication of WO2010093263A1 publication Critical patent/WO2010093263A1/en
Publication of WO2010093263A8 publication Critical patent/WO2010093263A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions for the treatment and/or prevention of cancer in a mammal by means of RNA interference are provided, together with methods for the use of such compositions. The compositions comprise a small interfering nucleic acid molecule (siNA) that suppresses expression of the YBX1 gene that is involved in RNA splicing and masking, translation, DNA repair and transcription.
PCT/NZ2010/000014 2009-02-03 2010-02-03 Compositions and methods for the treatment and prevention of neoplastic disorders Ceased WO2010093263A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14958209P 2009-02-03 2009-02-03
US61/149,582 2009-02-03

Publications (2)

Publication Number Publication Date
WO2010093263A1 WO2010093263A1 (en) 2010-08-19
WO2010093263A8 true WO2010093263A8 (en) 2010-09-30

Family

ID=42561948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2010/000014 Ceased WO2010093263A1 (en) 2009-02-03 2010-02-03 Compositions and methods for the treatment and prevention of neoplastic disorders

Country Status (1)

Country Link
WO (1) WO2010093263A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151063A1 (en) * 1996-08-30 2002-10-17 Annette Lasham Methods for modulating apoptotic cell death
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
EP2284266B1 (en) * 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
US20080145313A1 (en) * 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders

Also Published As

Publication number Publication date
WO2010093263A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
EP2379597B8 (en) Egfr-homing double-stranded rna vector for systemic cancer treatment
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2010056737A3 (en) Methods and compositions involving mirnas in cancer stem cells
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2008150897A3 (en) Reduction of off-target rna interference toxicity
WO2009105230A3 (en) Methods for treating cancer using combination therapy
IL311976A (en) Rna molecules
WO2008134646A3 (en) Rna interference suppression of neurodegenerative diseases and methods of use thereof
WO2010051502A3 (en) Light targeting molecules and uses thereof
WO2007093050A8 (en) Gene expression assays conducted by elemental analysis
CL2011000730A1 (en) Selection procedure for anti-cxcr4 antibodies and selected antibodies; nucleic acid encoding the antibodies; vector; host cell; production procedure; hybridoma that produces the antibodies; composition; use of selected antibodies to prepare a medicine to treat cancer.
BRPI1009576A2 (en) antibody, neutralizing antibody molecule, isolated DNA sequence, cloning or expression vector, host cell, process for producing the antibody, pharmaceutical composition, use of an antibody, and method for treating a patient.
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2006135684A3 (en) Methods and kits for sense rna synthesis
WO2010045384A3 (en) Short hairpin rnas for inhibition of gene expression
WO2011066263A8 (en) Transcription factor inhibitors and related compositions, formulations and methods
BRPI0815392A2 (en) METHOD FOR PRODUCING TRANSGENIC PLANT, TRANSGENIC PLANT, USE OF EXOGENIC NUCLEIC ACID SEQUENCE, CHEMERIC GENE, PLANT TRANSFORMATION VECTOR, AND PLANT OR PLANT CELL.
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2005110067A3 (en) Method and compositions for rna interference
EP4077677A4 (en) Rna nanoparticle for liver cancer treatment
WO2009143371A3 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
WO2010093263A8 (en) Compositions and methods for the treatment and prevention of neoplastic disorders
WO2010058393A3 (en) Compositions and methods for the prognosis of colon cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10741459

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10741459

Country of ref document: EP

Kind code of ref document: A1